<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00388583</url>
  </required_header>
  <id_info>
    <org_study_id>FID04</org_study_id>
    <nct_id>NCT00388583</nct_id>
  </id_info>
  <brief_title>Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects</brief_title>
  <official_title>Immunogenicity and Safety of The Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Standard Fluzone® in Ambulatory Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      As a result of the safety and immunogenicity data generated from earlier dose-ranging
      studies, the present formulation has been selected for further development in the elderly.

      Primary Objective:

      To compare the immunogenicity in subjects receiving investigational Fluzone with those of
      subjects receiving standard Fluzone®.

      Secondary Objectives:

      Immunogenicity:

      To describe the immunogenicity in subjects receiving investigational Fluzone and standard
      Fluzone®.

      Safety:

      To evaluate and describe the safety profile of investigational Fluzone in terms of solicited-
      and unsolicited adverse events and serious adverse events post-vaccination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With at Least a 4-Fold Increase in Serum HAI Antibody Titer Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine.</measure>
    <time_frame>Pre-vaccination and Day 28 post-vaccination</time_frame>
    <description>The serological determinations of total anti-influenza antibodies were performed using an Hemagglutinin inhibition (HAI) test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Achieved Seroprotection Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine.</measure>
    <time_frame>Day 28 post-vaccination</time_frame>
    <description>Seroprotection was defined as a post-vaccination Hemagglutinin inhibition (HAI) antibody titer ≥ 40</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Titers (GMTs) Before and Post-vaccination With Either Fluzone Intradermal and Fluzone Intramuscular Vaccine.</measure>
    <time_frame>Pre- and Day 28 post-vaccination</time_frame>
    <description>The serological determinations of total anti influenza antibodies were performed using an Hemagglutinin inhibition (HAI) test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting a Solicited Injection Site or Systemic Reaction, Post Vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine</measure>
    <time_frame>Day 0 up to 7 days post-vaccination</time_frame>
    <description>Solicited injection site reactions: Pain, Erythema, Swelling, Induration, Ecchymosis, and Pruritus.
Solicited systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">817</enrollment>
  <condition>Orthomyxoviridae Infection</condition>
  <condition>Influenza</condition>
  <condition>Myxovirus Infection</condition>
  <arm_group>
    <arm_group_label>Fluzone Intradermal (ID) Vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a dose of Fluzone Intradermal (ID) Influenza Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone Intramuscular (IM) Vaccine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received a dose of Fluzone Intramuscular (IM) Influenza Vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Split, Inactivated, Trivalent Influenza Vaccine</intervention_name>
    <description>0.1 mL, Intradermal</description>
    <arm_group_label>Fluzone Intradermal (ID) Vaccine Group</arm_group_label>
    <other_name>Fluzone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Split, Inactivated, Trivalent Influenza Vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Fluzone Intramuscular (IM) Vaccine Group</arm_group_label>
    <other_name>Fluzone® 2006/2007 Formulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥ 65 years on the day of vaccination.

          -  Informed consent form signed.

          -  Medically stable (Subjects may have underlying illnesses such as hypertension,
             diabetes, ischemic heart disease, congestive cardiac disorders or hypothyroidism, as
             long as their symptoms/signs are controlled).

          -  Able to attend all scheduled visits and to comply with all trial procedures.

        Exclusion Criteria:

          -  Systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine components,
             or a history of a life-threatening reaction to the standard-dose Fluzone® vaccine or a
             vaccine containing the same substances (the list of vaccine components is included in
             the Investigator's Brochure).

          -  Congenital or history of acquired immunodeficiency, or immunosuppressive therapy such
             as anti-cancer chemotherapy or radiation therapy within the preceding 6 months.

          -  Systemic corticosteroid therapy as follows:

          -  Continuous use with a dosage equivalent to &gt; 15 mg/day of oral prednisone for 90 days
             preceding vaccination

          -  Sporadic use with a dose of &gt; 40 mg/day of oral prednisone for &gt; 14 days in the 90
             days preceding vaccination.

        Note: Use of topical or inhalant corticosteroids is acceptable.

          -  Neoplastic disease or any hematologic malignancy (except localized skin or prostate
             cancer that is stable at the time of vaccination in the absence of therapy, as well as
             subjects who have a history of neoplastic disease and who have been disease-free for ≥
             5 years).

          -  Current abuse of alcohol or drug addiction that may interfere with the subject's
             ability to comply with trial procedures.

          -  Receipt of blood or blood-derived products in the past 3 months.

          -  Vaccination against influenza in the past 6 months.

          -  Any vaccination in the 4 weeks preceding the trial vaccination.

          -  Vaccination planned in the 4 weeks following the trial vaccination.

          -  Participation in another clinical trial in the 4 weeks preceding trial vaccination.

          -  Planned participation in another clinical trial during the present trial period.
             Concomitant participation in an observational trial (not involving drugs, vaccines, or
             medical devices) is acceptable.

          -  Chronic illness at a stage that could interfere with trial conduct or completion.

          -  Known current HIV, hepatitis B (HBsAg) or hepatitis C infection or seropositivity.

          -  Known thrombocytopenia or bleeding disorder contraindicating IM vaccination.

          -  Subject deprived of freedom by an administrative or court order, or in an emergency
             setting, or hospitalized without his/her consent.

          -  Acute illness and febrile illness with a temperature ≥ 38.0°C [or 100.4°F]) 72 hours
             before or on the day of inclusion.

          -  Received antibiotics therapy within 72 hours preceding the trial vaccination.

          -  Received any allergy shots in the 7-day period preceding trial vaccination and/or
             scheduled to receive any allergy shots in the 7-day period after trial vaccination.

          -  Any condition, which in the opinion of the investigator would pose a health risk to
             the participant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Alabaster</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bensalem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grove City</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2006</study_first_submitted>
  <study_first_submitted_qc>October 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2006</study_first_posted>
  <results_first_submitted>July 14, 2011</results_first_submitted>
  <results_first_submitted_qc>August 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 13, 2011</results_first_posted>
  <disposition_first_submitted>March 30, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>March 31, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 2, 2010</disposition_first_posted>
  <last_update_submitted>April 13, 2012</last_update_submitted>
  <last_update_submitted_qc>April 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Orthomyxoviruses</keyword>
  <keyword>Inactivated Split-virion influenza vaccine</keyword>
  <keyword>Elderly.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Orthomyxoviridae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 28 September 2006 through 30 May 2007 in 16 clinics in the US</recruitment_details>
      <pre_assignment_details>A total of 816 of the 817 participants that met the inclusion and exclusion criteria were enrolled and vaccinated. Data on the 807 participants that completed the study are presented.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fluzone Intradermal (ID) Vaccine Group</title>
          <description>Participants received a dose of Fluzone Intradermal vaccine on Day 0</description>
        </group>
        <group group_id="P2">
          <title>Fluzone Intramuscular (IM) Vaccine Group</title>
          <description>Participants received a dose of Fluzone Intramuscular vaccine on Day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="407"/>
                <participants group_id="P2" count="410"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="401"/>
                <participants group_id="P2" count="406"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive vaccine</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluzone ID Vaccine Group</title>
          <description>Participants received a dose (0.1 mL) of Fluzone intradermal vaccine on Day 0.</description>
        </group>
        <group group_id="B2">
          <title>Fluzone IM Vaccine Group</title>
          <description>Participants received a dose (0.5 mL) of Fluzone intramuscular vaccine on Day 0.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="401"/>
            <count group_id="B2" value="406"/>
            <count group_id="B3" value="807"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="401"/>
                    <measurement group_id="B2" value="406"/>
                    <measurement group_id="B3" value="807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.8" spread="6.08"/>
                    <measurement group_id="B2" value="72.3" spread="5.83"/>
                    <measurement group_id="B3" value="72.5" spread="5.955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="401"/>
                    <measurement group_id="B2" value="406"/>
                    <measurement group_id="B3" value="807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With at Least a 4-Fold Increase in Serum HAI Antibody Titer Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine.</title>
        <description>The serological determinations of total anti-influenza antibodies were performed using an Hemagglutinin inhibition (HAI) test.</description>
        <time_frame>Pre-vaccination and Day 28 post-vaccination</time_frame>
        <population>Immunogenicity determination was in all per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Intradermal (ID) Vaccine Group</title>
            <description>Participants received a dose of Fluzone Intradermal vaccine on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Intramuscular (IM) Vaccine Group</title>
            <description>Participants received a dose of Fluzone Intramuscular vaccine on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least a 4-Fold Increase in Serum HAI Antibody Titer Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine.</title>
          <description>The serological determinations of total anti-influenza antibodies were performed using an Hemagglutinin inhibition (HAI) test.</description>
          <population>Immunogenicity determination was in all per protocol population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Serogroup (N = 400, 406)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="105" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Serogroup (N = 398, 404)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235"/>
                    <measurement group_id="O2" value="222" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Serogroup (N = 400, 405)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="103" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Titers (GMTs) Before and Post-vaccination With Either Fluzone Intradermal and Fluzone Intramuscular Vaccine.</title>
        <description>The serological determinations of total anti influenza antibodies were performed using an Hemagglutinin inhibition (HAI) test.</description>
        <time_frame>Pre- and Day 28 post-vaccination</time_frame>
        <population>Immunogenicity determination was in all per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Intradermal (ID) Vaccine Group</title>
            <description>Participants received a dose of Fluzone Intradermal vaccine on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Intramuscular (IM) Vaccine Group</title>
            <description>Participants received a dose of Fluzone Intramuscular vaccine on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers (GMTs) Before and Post-vaccination With Either Fluzone Intradermal and Fluzone Intramuscular Vaccine.</title>
          <description>The serological determinations of total anti influenza antibodies were performed using an Hemagglutinin inhibition (HAI) test.</description>
          <population>Immunogenicity determination was in all per protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Serogroup (Pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.46" lower_limit="24.81" upper_limit="30.40"/>
                    <measurement group_id="O2" value="24.86" lower_limit="22.33" upper_limit="27.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Serogroup (Post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.17" lower_limit="63.93" upper_limit="79.22"/>
                    <measurement group_id="O2" value="59.04" lower_limit="53.27" upper_limit="65.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Serogroup (Pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.95" lower_limit="65.42" upper_limit="88.17"/>
                    <measurement group_id="O2" value="64.95" lower_limit="55.91" upper_limit="75.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Serogroup (Post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500.65" lower_limit="442.40" upper_limit="566.56"/>
                    <measurement group_id="O2" value="360.42" lower_limit="317.68" upper_limit="408.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Serogroup (Pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.11" lower_limit="12.08" upper_limit="14.22"/>
                    <measurement group_id="O2" value="12.95" lower_limit="11.93" upper_limit="14.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Serogroup (Post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.06" lower_limit="31.91" upper_limit="38.53"/>
                    <measurement group_id="O2" value="35.77" lower_limit="32.44" upper_limit="39.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Achieved Seroprotection Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine.</title>
        <description>Seroprotection was defined as a post-vaccination Hemagglutinin inhibition (HAI) antibody titer ≥ 40</description>
        <time_frame>Day 28 post-vaccination</time_frame>
        <population>Immunogenicity determination was in all per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Intradermal (ID) Vaccine Group</title>
            <description>Participants received a dose of Fluzone Intradermal vaccine on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Intramuscular (IM) Vaccine Group</title>
            <description>Participants received a dose of Fluzone Intramuscular vaccine on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved Seroprotection Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine.</title>
          <description>Seroprotection was defined as a post-vaccination Hemagglutinin inhibition (HAI) antibody titer ≥ 40</description>
          <population>Immunogenicity determination was in all per protocol population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Serogroup (N = 400, 406)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303"/>
                    <measurement group_id="O2" value="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Serogroup (N = 398, 405)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391"/>
                    <measurement group_id="O2" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Serogroup (N = 400, 406)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                    <measurement group_id="O2" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reaction, Post Vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine</title>
        <description>Solicited injection site reactions: Pain, Erythema, Swelling, Induration, Ecchymosis, and Pruritus.
Solicited systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia.</description>
        <time_frame>Day 0 up to 7 days post-vaccination</time_frame>
        <population>Safety analysis was on all enrolled and vaccinated participants, intend-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Intradermal (ID) Vaccine Group</title>
            <description>Participants received a dose of Fluzone Intradermal vaccine on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Intramuscular (IM) Vaccine Group</title>
            <description>Participants received a dose of Fluzone Intramuscular vaccine on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reaction, Post Vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine</title>
          <description>Solicited injection site reactions: Pain, Erythema, Swelling, Induration, Ecchymosis, and Pruritus.
Solicited systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia.</description>
          <population>Safety analysis was on all enrolled and vaccinated participants, intend-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Injection Site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Pain (Incapacitating)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Erythema (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Swelling (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Induration (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Ecchymosis (Incapacitating)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Pruritus (Incapacitating)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Solicited Fever (&gt;102.2°F)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gr 3 Solicited Headache- Prevents daily activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grd 3 Solicited Malaise- Prevents daily activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grd 3 Solicited Myalgia- Prevents daily activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination up to 6 months post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fluzone Intradermal (ID) Vaccine Group</title>
          <description>Participants received a dose of Fluzone Intradermal vaccine on Day 0</description>
        </group>
        <group group_id="E2">
          <title>Fluzone Intramuscular (IM) Vaccine Group</title>
          <description>Participants received a dose of Fluzone Intramuscular vaccine on Day 0</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enterovesical Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Small intestine obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Device electric finding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus non insulin dependent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Joint instability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Benign renal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Transuerethral prostatectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Leriche syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="282" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="407"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Solicited injection site pain</sub_title>
                <counts group_id="E1" events="105" subjects_affected="105" subjects_at_risk="402"/>
                <counts group_id="E2" events="98" subjects_affected="98" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Solicited injection site erythema</sub_title>
                <counts group_id="E1" events="282" subjects_affected="282" subjects_at_risk="402"/>
                <counts group_id="E2" events="49" subjects_affected="49" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Solicited injection site induration</sub_title>
                <counts group_id="E1" events="178" subjects_affected="178" subjects_at_risk="400"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Solicited injection site ecchymosis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="400"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Solicited injection site pruritus</sub_title>
                <counts group_id="E1" events="137" subjects_affected="137" subjects_at_risk="402"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Solicited malaise</sub_title>
                <counts group_id="E1" events="57" subjects_affected="57" subjects_at_risk="402"/>
                <counts group_id="E2" events="41" subjects_affected="41" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Solicited myalgia</sub_title>
                <counts group_id="E1" events="68" subjects_affected="68" subjects_at_risk="402"/>
                <counts group_id="E2" events="56" subjects_affected="56" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Solicited injection site swelling</sub_title>
                <counts group_id="E1" events="186" subjects_affected="186" subjects_at_risk="402"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Solicited headache (Pyrexia)</sub_title>
                <counts group_id="E1" events="69" subjects_affected="69" subjects_at_risk="402"/>
                <counts group_id="E2" events="63" subjects_affected="63" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

